A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
Table 2
Changes in β-cell function and insulin sensitivity from baseline to day 12 in patients treated with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).
Indices†
Group A ()
Group B ()
value for group comparison
Baseline AUC insulin (h·mU/L)
35.83 ± 24.99
36.34 ± 23.21
0.932
△AUC (h·mU/L)‡
19.59 (6.50–31.19)
27.24 (14.49–51.83)
0.060
Baseline AUC C-peptide (h·nmol/L)
1.50 ± 0.70
1.46 ± 0.62
0.826
△AUC C-peptide (h·nmol/L)‡
0.45 (−0.04–0.72)§
0.62 (0.21–1.05)§
0.323
Baseline LnHOMA-IR
1.43 ± 0.48
1.30 ± 0.62
0.355
△LnHOMA-IR
−0.56 ± 0.63§
−0.33 ± 0.53§
0.113
Baseline LnHOMA-β
2.85 ± 0.77
2.81 ± 0.90
0.828
△LnHOMA-β
1.06 ± 0.82§
2.36 ± 0.98§
0.000
Baseline CPI
0.70 ± 0.43
0.72 ± 0.39
0.867
△CPI
0.34 ± 0.32§
0.74 ± 0.49§
0.000
Baseline SUIT
15.76 ± 12.36
16.22 ± 10.39
0.870
△SUIT
18.01 ± 12.31§
63.99 ± 47.70§
0.000
Baseline IGI 30 minutes
1.91 ± 2.19
1.56 ± 1.66
0.464
△IGI 30 minutes
1.33 ± 3.00§
2.64 ± 2.64§
0.06
Baseline ISSI-2‡
49.76 (38.39–75.68)
63.90 (36.51–113.25)
0.568
△ISSI-2‡
136.30 (109.22–184.83)§
212.51 (168.25–268.80)§
0.000
Baseline PI/IRI %‡
36.0 (24.9–64.6)
37.9 ± 24.5
0.401
△PI/IRI%‡†
−21.8 (−35.6–4.9)§
−26.5 ± 24.6§
0.432
†Data are mean (standard deviation) unless otherwise stated; ‡median (range); §significant change from baseline (). △: change from baseline; AUC: area under the curve; ISSI: insulin secretion sensitivity index; HOMA-β: homeostatic model assessment of β-cell function; CPI: C-peptide reactivity index; SUIT: the secretory unit of islet in transplantation index; IGI: insulinogenic index; PI/IRI: ratio of proinsulin to immunoreactive insulin; HOMA-IR: homeostatic model assessment or insulin resistance.
